Gallop Oncology
LYT-200
relapsed/refractory high-risk myelodysplastic syndrome
Resolved
188days ago
Phase 2 readout · Dec 31, 2025
What's at stake
Phase 2 trial results for LYT-200 in relapsed/refractory high-risk myelodysplastic syndrome are due Dec 31, 2025. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“December 2025: Presented initial topline results from the Phase 1b clinical trial of LYT-200 in patients with R/R HR-MDS and R/R AML at the American Society of Hematology Annual Meeting.”